The Roche Column

Roche Diagnostics brings the power of knowing the value of diagnostics in healthcare


Diagnostics are becoming increasingly important for healthcare providers to deliver an objective source of information and the most optimized care to patients. With quality tools for diagnosis, clinicians can have access to accurate and reliable results in the right time; this equips them with the resources and knowledge to make the
correct diagnosis, implement the best treatment and limit disease progression by predicting the care needed for the best patient outcome.

The value of diagnostics lies in having the right information available, which is why Roche Diagnostics believes in ‘the power of knowing’ – a term used to define the value diagnostics brings to our health.

Diagnostics are more than just a precursor to treatment; they are about intervention. The power of knowing allows healthcare professionals to manage disease and deliver the best possible patient care. As such, it is of paramount importance that the diagnostic tools used are reliable and accurate. Roche Diagnostics is fully committed to building strong and lasting partnerships with laboratories to provide fast and reliable results needed for life-changing decisions.

The broad range of tests offered by Roche Diagnostics, together with their cutting-edge technologies, contributes to a new phase of sustainable healthcare in disease prevention and management. This involves the integration of multiple areas: prevention, prediction and treatment, which can be found in Roche’s broad range of solutions in areas such as oncology and women’s health.

While cervical cancer is the second most common cancer in women between the age of 15 and 441, it can be prevented with early detection to improve patient outcomes. The average 5-year survival rate is estimated to be 90% for cervical cancer2, demonstrating the value of early detection. Similarly, breast cancer is another common cancer in women worldwide, according to the World Health Organization (WHO). Approximately 15 –25% of breast cancers cases are positive for human epidermal growth factor 2 (HER2)3. With early detection, the average 5-year survival rate is estimated to be 89% for breast cancer4. With Roche’s personalised healthcare tests cancer clinicians can better stratify their patients, depending on their diagnosis, into the best treatment decision, eliminating trial and error and saving time, costs, and most importantly, lives.

Early detection and diagnosis is also important in pre-eclampsia, which occurs in 3–5% of pregnancies during the second half of gestation5. It is usually difficult to diagnose due to variable features and unspecific symptoms, but with the test to detect soluble form of vascular endothelial growth factor receptor and placental growth factor (sFlt-1/PlFG), clinicians can predict the risk of complications at birth. Subsequent administration of special care and monitoring can then protect the health and safety of the mother and child.

Roche Diagnostics is investing in pushing the boundaries through innovation so that the development of products and solutions that help predict and prevent disease can be consistently delivered. Through the Power of Knowing, healthcare professionals can make the right decisions for their patients at the right time. Roche Diagnostics offers the industry’s broadest range of tests and pioneering technologies, the solutions can give an accurate diagnosis, detect risk of disease, predict how disease may progress, and enable the right treatment decision to be made at the first opportunity.


1 - World Health Organization. 1 in 100 women in Europe will develop cervical cancer. Available online: http:// noncommunicable-diseases/cancer/ news/news/2013/04/1-in-100-women-ineurope- will-develop-cervical-cancer

2 - A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007

3 - WebMD, Breast Cancer Health Centre. Last accessed March 2014 at breast-cancer-types-er-positive-her2-positive

4 - National Cancer Institute. SEER Cancer Statistics Review 1975-2010. Last accessed March 2014 at http://seer. topic_survival.pdf

5 - Roberts, J. M., & Cooper, D. W. (2001). Pathogenesis and genetics of preeclampsia. The Lancet, 357, 53-56.

 Date of upload: 11th May 2016


                                               Copyright © 2015 All Rights Reserved.